Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, ...

Human pluripotent stem-cells (HPSCs)—including human embryonic stem-cells and human induced pluripotent stem-cells—are reshaping the landscape of regenerative medicine.1,2 In Parkinson's disease, ...

An expert panel formed to recommend changes has submitted its final report, and the Centre has now issued an office order assigning specific reforms to concerned divisions of CDSCO ...

Market expansion in med derm cross over: Almirall’s Seysara (sarecycline) won NMPA approval for moderate to severe acne (≥9 years), with China commercial launch targeted for 2026 – relevant to ...

Frailty can typically only be lessened through lifestyle changes, but a stem cell therapy seems to target the underlying ...

Rare Disease Day is held on the last day of February to raise awareness for rare diseases and address drug development ...

O3, Lauren Goodwin, New York Life Investments, appeared on CNBC’s ‘Closing Bell’ to talk about the state of equity markets ...

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with ...

Recent medical advances in gene and cell therapies have renewed hope for some patients with aggressive blood cancers.

Hospitals and cancer centers that are launching cell and gene therapy programs need more than scientific breakthroughs to succeed. Delivering these therapies safely and efficientl ...

Researchers at the Sanford Stem Cell Institute have taken the fight against rare diseases to the lab, to patients’ bedsides ...

Metabolon helped Kite study the link between metabolic signatures and the severity of neurological evens in samples from ...